Transgenic and pharmacological studies in mice have demonstrated the beneficial effects of MGAT inhibition as a therapy for treating several metabolic diseases, including obesity, insulin resistance, T2D, and NAFLD. Here, MGAT1 is linked to metabolic dysfunction-associated steatotic liver disease.